NeuroEvidence: AI Clinical Research Intelligence for Neurology

Neurological conditions are now the leading cause of ill health and disability worldwide, affecting more than 3 billion people globally. That is more than 1 in 3 people on the planet.

According to the World Health Organization, neurological conditions account for over 11 million deaths every year. The overall disease burden has grown by 18% since 1990, spanning conditions from Alzheimer's Disease and Parkinson's to Multiple Sclerosis, epilepsy, and beyond.

The scientific response has been enormous. Millions of papers across the neuroscience and neurological research corpus are published annually. New clinical evidence, biomarker discoveries, and trial data enter the literature every week across conditions.

The core bottleneck in neurological clinical research is the inability to synthesise this evidence accurately, quickly, and at the scale that modern clinical research demands.

In areas like Alzheimer's Disease and MCI, for instance, where the published evidence base runs to hundreds of thousands of papers on a single condition alone, this problem is especially acute. Researchers are drowning in the very evidence that should be helping them.

This is the problem NeuroEvidence was built to solve.

Why General-Purpose Medical AI Tools Fall Short in Neurological Research

General-purpose medical AI tools have transformed how researchers access information. They retrieve sources, generate summaries, and provide citations across vast datasets. For many use cases, they are highly effective.

However, neurological clinical research introduces a different level of complexity.

The challenge is not retrieving more information. It is retrieving the right information pre-filtered by clinical relevance before synthesis begins.

This includes:

1. Species (human vs non-human)
2. Condition specificity
3. Disease stage
4. Study intent
5. Evidence quality

These requirements are not reliably enforced through prompting alone, particularly at scale.

A researcher can instruct a system to focus on human studies. But that instruction competes with all other contexts in the query. There is no guarantee it will be applied consistently across hundreds of retrieved documents. Further prompting to guide a general LLM to distinguish studies based on the conditions or evidence quality will produce a wide range of performance.

More importantly, these systems lack built-in awareness of critical clinical distinctions:

1. Diagnostic vs prognostic studies
2. Early vs moderate vs advanced disease stages
3. Biomarker vs therapeutic research

These are not subtleties that can be teased apart using prompt-level preferences. They are structural requirements defined at the indexing and retrieval layer, before any query is processed.

The difference is not the model. It is the structure imposed on evidence before the model reads anything.

Where Standard Workflows Break Down

These limitations are not incremental. They are architectural.

• No pre-retrieval filtering — Relevance depends heavily on how the question is phrased. There is no consistent system-level filtering before retrieval.
• No domain-specific representation — Most systems rely on general biomedical embeddings, with limited neurological specialization.
• No systematic evidence weighting — Study design and methodological rigor are not consistently prioritised during synthesis.
• Cross-document interference — Multiple studies are processed together, allowing findings from one paper to influence interpretation of another.
• Limited verification — Outputs are primarily text-based, with limited ability to directly inspect underlying evidence such as figures, tables, or extracted findings.

Introducing NeuroEvidence: Evidence Engineering, Not Search

NeuroEvidence is NeuroDiscovery AI's AI-native clinical research intelligence system designed for neurological research, built to handle the scale, complexity, and variability of clinical evidence across conditions.

Not a chatbot that hallucinates citations. Not a search engine that returns blue links. Something meaningfully different.

The design philosophy at the core of NeuroEvidence is this:

Clinical evidence systems must be recall-first, filter-driven, and synthesis-last. The AI synthesises only after the evidence has been rigorously filtered. Not before.

The Evidence Funnel: From Millions of Papers to Clinical-Grade Answers

The most important architectural decision in NeuroEvidence is not about the AI model. It is about what happens before the AI reads anything, because, simply put, data quality is essential.

Starting from a corpus of millions of neuroscience and neurological research papers, NeuroEvidence applies a series of strict "Hard Gates" offline filters that narrow the evidence pool to only what is clinically relevant to the query. Here is how that funnel works in practice, using Alzheimer's Disease and MCI as an illustration:

The Evidence Narrowing Funnel: AD/MCI Example

Stage 1 — Species Filter

Restricts results to human studies only. This single filter eliminates 60–70% of neuroscience literature instantly, removing animal studies and in-vitro experiments that have no clinical relevance to a question about a human patient.

Stage 2 — Condition Filter

Restricts to the target neurological condition of the query, preventing cross-condition leakage. Research from unrelated neurological conditions does not contaminate the evidence pool. In Alzheimer's Disease and MCI research, this means excluding Parkinson's, Multiple Sclerosis, Frontotemporal Dementia, and other conditions unless specifically relevant.

Stage 3 — Population Stage Filter

Matches the query to the exact population stage being studied. Across neurological conditions, disease stage determines everything; biomarker performance, drug efficacy, and prognosis all differ meaningfully between stages. In Alzheimer's Disease and MCI research, for example, the system distinguishes between Preclinical AD, Prodromal AD, Early/Mild AD, Moderate AD, Severe AD, Amnestic MCI, Non-amnestic MCI, and others. This filter reduces the candidate pool by a further 3–5 times.

Stage 4 — Study Intent Filter

Separates papers by what they were designed to do: Diagnosis, Prognosis, Treatment, Biomarker validation, or Risk Factor assessment. A diagnostic accuracy study tells you almost nothing about a prognostic question. This filter removes 50–70% of otherwise relevant disease papers.

Stage 5 — Evidence Tier Filter

Prioritises evidence by publication quality:

• Tier 1 (Meta-analyses and Phase III RCTs)
• Tier 2 (Phase II RCTs and large cohorts)
• Tier 3 (case-control and cross-sectional studies)
• Tier 4 (narrative reviews and opinion pieces)

Excluding Tier 4 alone removes an additional 30–40% of the remaining pool.

The result: approximately 2,000 rigorously filtered articles enter retrieval. That is the pool the AI works with. Nothing else.

How NeuroEvidence Reads and Synthesises Evidence

Evidence-Aware Chunking

Rather than splitting papers at arbitrary token boundaries, NeuroEvidence segments each article into atomic evidence units. Discussion sections are excluded from retrieval entirely, preventing author speculation from contaminating the synthesis. The system also strips hedging language from conclusions, so only what was actually found enters the evidence pool.

Dual Embedding Models

Each evidence unit is indexed using two complementary models: a fine-tuned neuroscience model for disease-specific semantic nuance, and BioLORD for broader biomedical coverage. A query is matched against both, and the higher score wins. Each model has different blind spots. Together, they are significantly more robust than either alone.

The LLM Council: Parallel Evidence Extraction

Rather than one model reasoning over all retrieved papers at once which causes evidence from different studies to contaminate each other NeuroEvidence deploys the LLM Council: a structured ensemble where each individual agent analyses exactly one paper in complete isolation, extracting claims, effect sizes, populations, and statistical significance.

The LLM Council then synthesises across all structured outputs, resolving conflicts, weighting findings by evidence tier, integrating visual evidence from figures and tables, and generating a final answer that is fully traceable to its sources.

No output is released without passing two independent audits: a Completeness audit ensuring no clinical finding was missed, and a Reasoning audit flagging unsupported inferences.

What the Researcher Actually Sees

When a source paper contains a relevant figure showing biomarker progression curves, the researcher sees that figure extracted directly from the paper. When a study includes a comparison table of drug efficacy across disease stages, the researcher sees that table.

Every claim in a NeuroEvidence response traces back to a specific PMC article, a specific chunk within that article, and a specific finding from that chunk. Evidence consistency across studies is flagged. Gaps in the literature are noted.

The AI shows its work. Every answer comes with the actual images, tables, and papers it drew from, so you can verify, not just accept.

Two Modes for Two Different Research Needs

Fast Mode

Before you can run a full evidence synthesis, you need to know the right question to ask.

Fast Mode is designed for that earlier phase, when a researcher is testing a hypothesis, scoping a new research direction, or checking whether a meaningful evidence base exists before committing to a full literature review.

Keyword-driven retrieval across indexed PubMed Central articles surfaces relevant papers quickly, with citations and full traceability. It is precise enough to sharpen a research hypothesis. It is not designed to replace the depth of a full evidence synthesis.

Think of it as the tool that tells you whether the question is worth asking and helps you frame it correctly before Deep Think answers it definitively.

Deep Think Mode: Powered by the LLM Council

Built for the questions where accuracy is everything and the answer will inform a clinical decision, a regulatory submission, or a research publication.

Full semantic retrieval, cross-encoder reranking, parallel LLM Council processing, and master-level synthesis. The kind of structured literature review that would take a dedicated research team several days or weeks completed in minutes. Built for the questions where accuracy is everything.

The difference between Fast Mode and Deep Think is not speed. It is the stage of research you are in.

Analysis You Can Actually Act On

Beyond the core synthesis, NeuroEvidence generates structured outputs your team can act on immediately:

• Comparison tables — side-by-side analysis across drugs, biomarkers, or patient populations, structured for direct evaluation without manual cross-referencing.
• Evidence trend charts — visualisations showing how published science on a specific question has evolved across publication years, so researchers can see not just what the evidence says today but how confident the field has become over time.
• Stage-stratified summaries — across neurological conditions, disease stage determines everything. In Alzheimer's Disease and MCI, for example, MCI, Early AD, and Moderate AD are not the same clinical question. The answers the evidence gives are often completely different across these populations, and NeuroEvidence accounts for that.

When evidence is inconsistent across studies, the platform flags it. When gaps exist in the literature, they are noted. A NeuroEvidence response does not pretend the science is cleaner than it is.

Who NeuroEvidence Is Built For

NeuroEvidence is designed for clinical researchers, R&D leaders, and medical affairs teams working across neurological research people managing enormous evidence loads, under real time pressure, in a domain where accuracy is not optional.

It sits within NeuroDiscovery AI's broader platform for neurology clinical research, which includes access to 5.3M + U.S. neurology patient records, real-world evidence generation, and patient recruitment for clinical trials.

If your team is spending days on literature reviews that should take hours, using tools that cannot explain their own answers, or struggling to stay current with a field that moves this fast then this platform was built for you.

Frequently Asked Questions

1. What makes NeuroEvidence different from general-purpose medical AI tools?

Unlike general medical AI tools, NeuroEvidence filters evidence through five architectural Hard Gates before processing, weights findings by publication tier, and ensures every claim is directly traceable to specific source documents rather than treating all unvalidated data equally.

2. What neurological conditions does NeuroEvidence support?

NeuroEvidence is built for neurological clinical research broadly, designed to handle the scale, complexity, and variability of clinical evidence across conditions. The platform uses Alzheimer's Disease and MCI as a primary demonstration area given the depth and density of that evidence base, but the architecture applies across the neurological research landscape.

3. What is the LLM Council?

The LLM Council is NeuroEvidence's multi-agent evidence extraction architecture. Rather than one model processing all papers simultaneously, which causes cross-paper contamination, individual agents each process a single article in isolation before a Master agent synthesises their outputs. This preserves the integrity of individual citations and makes the final answer fully traceable.

4. What sources does NeuroEvidence draw from?

NeuroEvidence indexes millions of PubMed Central (PMC) articles filtered for neurological research, applying condition-specific, stage-specific, and intent-specific filtering before any AI processing.

5. How do I see NeuroEvidence in action?

Book a 20-minute walkthrough with your own research question. You will see exactly how the platform answers it and where every piece of that answer comes from.

Ready to See NeuroEvidence Answer Your Research Questions?

Bring your own clinical question. See the evidence it retrieves, the figures it surfaces, and the sources every claim traces back to.

▶ Book a 20-minute walkthrough → neurodiscovery.ai/contact

▶ Explore NeuroDiscovery AI's full neurology platform → neurodiscovery.ai

▶ Explore our Data & Research capabilities → neurodiscovery.ai/data-and-research